A CD47-blocking TRAIL Fusion Protein With Dual Pro-Phagocytic and Pro-Apoptotic Anticancer Activity

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.12617
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Glycosylation Modulates TRAIL-R1/death Receptor 4 Protein: Different Regulations of Two Pro-Apoptotic Receptors for TRAIL by Tunicamycin

Oncology Reports
MedicineCancer ResearchOncology
2007English

Mapping the Interaction of Pro-Apoptotic tBID With Pro-Survival BCL-XL

Biochemistry
Biochemistry
2009English

A Dual-Role of Gu-4 in Suppressing HMGB1 Secretion and Blocking HMGB1 Pro-Inflammatory Activity During Inflammation

PLoS ONE
Multidisciplinary
2014English

Involvement of Pro-Apoptotic and Pro-Autophagic Proteins in Granulosa Cell Death

Cell Biology
2013English

Mapping the Specific Cytoprotective Interaction of Humanin With the Pro-Apoptotic Protein Bid

Chemical Biology and Drug Design
BiochemistryOrganic ChemistryDrug DiscoveryMolecular MedicinePharmacology
2007English

The Identification of a CD47-blocking “Hotspot” and Design of a CD47/PD-L1 Dual-Specific Antibody With Limited Hemagglutination

Signal Transduction and Targeted Therapy
Cancer ResearchGenetics
2020English

Double-Edged Lipid Nanoparticles Combining Liposome-Bound TRAIL and Encapsulated Doxorubicin Showing an Extraordinary Synergistic Pro-Apoptotic Potential

Cancers
Cancer ResearchOncology
2019English

The Development of Pro-Apoptotic Cancer Therapeutics

Mini-Reviews in Medicinal Chemistry
MedicineDrug DiscoveryPharmacology
2008English

Mutating RBF Can Enhance Its Pro-Apoptotic Activity and Uncovers a New Role in Tissue Homeostasis

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy